| 0.9626 0.103 (11.93%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.55 | 1-year : | 1.93 |
| Resists | First : | 1.32 | Second : | 1.65 |
| Pivot price | 0.9  |
|||
| Supports | First : | 0.79 | Second : | 0.65 |
| MAs | MA(5) : | 0.86  |
MA(20) : | 1 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 11.7 |
| RSI | RSI(14): 38.7 |
|||
| 52-week | High : | 20.65 | Low : | 0.79 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AIDX ] has closed below upper band by 31.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 0.99 - 0.99 | 0.99 - 1 |
| Low: | 0.79 - 0.8 | 0.8 - 0.8 |
| Close: | 0.95 - 0.96 | 0.96 - 0.97 |
20/20 GeneSystems, Inc. operates as a specialized clinical diagnostic company, focusing primarily on screening for cancer and analyzing viral infections. The firm offers advanced blood tests for the early detection of various cancers, including a notable product called OneTest. Additionally, it provides services for identifying viruses, such as rapid COVID-19 test kits like the Assure COVID-19 IgG/IgM rapid assay. The company also manages the Clinical Lab Innovation Axcelerator (CLIAx), a collaborative laboratory space designed to help developers of diagnostic products bring their innovations to the U.S. market. Furthermore, 20/20 GeneSystems delivers its cancer screening algorithm technology to healthcare providers via a software-as-a-service (SaaS) platform. It actively supports emerging diagnostic startups by offering them access to shared lab infrastructure and vital resources. Founded in 2000, the company is headquartered in Gaithersburg, Maryland.
Fri, 12 Jun 2026
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Wed, 27 May 2026
20/20 Biolabs, Inc. Files Form 8-K Announcing Amended and Restated Bylaws and Nasdaq Listing as Emerging Growth Company – Minichart - Minichart
Fri, 22 May 2026
AIDX Stock Slides As 20/20 Biolabs Tests Key Support - timothysykes.com
Wed, 20 May 2026
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress - GlobeNewswire
Wed, 25 Feb 2026
New AI blood test ties inflammation and disease risk to your diet - Stock Titan
Mon, 23 Feb 2026
20/20 Biolabs, Inc. Common Stock (AIDX) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 11 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 34.7 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 19 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.23 |
| Profit Margin | -279.2 % |
| Operating Margin | -408.5 % |
| Return on Assets (ttm) | -58.9 % |
| Return on Equity (ttm) | -241.6 % |
| Qtrly Rev. Growth | -36.3 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.17 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -1.97 |
| PEG Ratio | 0 |
| Price to Book value | 4.01 |
| Price to Sales | 5.55 |
| Price to Cash Flow | -3.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|